SAGE News and Press, Sage Therapeutics Inc. From 10/12/21

With the US Q3 earnings season just getting started, there are a few biotech stocks that present an exciting opportunity for value investors. Some of these stocks look significantly undervalued after a decline in their stock prices. Regeneron Pharmaceuticals Regeneron Pharmaceut...

Biogen is one of the leading providers of medicines used for the treatment of multiple sclerosis, spinal muscular atrophy. Biogen's gross margin is around 83.4%, significantly higher than the medical industry average and one of the highest among the top 20 pharmaceutical companies in ...

Improvement in measurements of overall quality of life, functioning and general well-being achieved at Day 15 and sustained at Day 42 Consistent and differentiated safety and tolerability profile seen across clinical programs Sage to host conference call on October 4, ...

Effort embodies Sage’s long-term commitment to investing in People, Patients, Planet and Community Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitati...

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the appointment of Chris Benecchi as Chief Commercial Officer. In his new r...

Sage Therapeutics, Inc. (Nasdaq:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Trac...

The WHO predicts that depression will be the biggest problem in the world during the next decade and beyond. GH Research had a rather successful IPO on the 24th of June. Investing in biotech may be the way to go for investors looking for large gains over the long term. For f...

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, announced today that the Company will present at the following upcoming investor conf...

Image source: The Motley Fool. Sage Therapeutics Inc (NASDAQ: SAGE) Q2 2021 Earnings Call Aug 3, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Sage Therapeutics Inc (SAGE) Q2 2021 Earnings Call Transcript

SAGE Therapeutics, Inc. (SAGE) Q2 2021 Earnings Conference Call August 03, 2021, 08:00 ET Company Participants Jeff Boyle - Investor Contact Barry Greene - President, CEO & Director Stephen Kanes - Chief Medical Officer Kimi Iguchi - CFO & Treasurer Conference Call Participants Paul M...